The role of real-world data in advancement of Alzheimer’s treatments
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that...
One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that...
RWE and HEOR teams face increasing pressure to produce evidence that holds up beyond internal...
Healthcare marketing has reached an inflection point and for years, success was defined by reach:...
Capturing the true complexity of psoriasis in the real world Psoriasis is a common chronic...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Real-world evidence (RWE) studies often stall on the same friction points: defining the most...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
October is Breast Cancer Awareness Month. While pink ribbons and fundraising campaigns help bring...
We put the newest HealthVerity eXOs capabilities to the test on one of the most-watched questions in healthcare: who is starting GLP-1s, where they are and what happens next. Here is what the new features did and what the data revealed.